-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-345 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-345 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-345 in Solid Tumor Drug Details: IBI-345 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-345 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-345 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-345 in Pancreatic Cancer Drug Details: IBI-345 is under development for...
-
Product Insights
NewMELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2024
Empower your strategies with our MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2024 report and make more profitable business decisions. Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is one of the family of mitochondrial diseases. A feature of this diseases is that it is caused by defects in the mitochondrial genome which is inherited purely from the female parent. The most common MELAS mutation is mitochondrial mutation, mtDNA, referred to as m.3243A>G. Symptoms typically...
-
Product Insights
NewMitochondrial Myopathy – Drugs In Development, 2024
Empower your strategies with our Mitochondrial Myopathy – Drugs In Development, 2024 report and make more profitable business decisions. Mitochondria are known as "the powerhouse of the cell," but when defects occur they give rise to mitochondrial diseases. Mitochondrial diseases affecting the muscles are known as mitochondrial myopathies. These can occur because of fetal gene mutations in the mitochondria, resulting in childhood myopathies. Symptoms include fatigue, muscle weakness, stunted growth, and exercise intolerance, as production of adenosine triphosphate (ATP), a cellular...
-
Product Insights
NewNet Present Value Model: Takeda Pharmaceutical Co Ltd’s TAK-214
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Reneo Pharmaceuticals Inc’s REN-001
Empower your strategies with our Net Present Value Model: Reneo Pharmaceuticals Inc's REN-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Reneo Pharmaceuticals Inc’s Mavodelpar
Empower your strategies with our Net Present Value Model: Reneo Pharmaceuticals Inc's Mavodelpar report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mavodelpar sodium in Glycogen Storage Disorders (GSD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mavodelpar sodium in Glycogen Storage Disorders (GSD) Drug Details: Mavodelpar sodium (REN-001) is under development for...